Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Lipidology

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacl.2008.10.004PMID 21291778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standards of Medical Care in Diabetes—2008 The recommendations in this article are based on the evidence reviewed in the following publication: Standards of care for diabetes (Technical Review). Diabetes Care 17:1514–1522, 1994. Originally approved 1988. Most recent review/revision, October 2007.

  2008cited by this paper
• Standards of Medical Care in Diabetes—2008

  2008cited by this paper
• High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate

  2007cited by this paper
• Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy:

  2007cited by this paper
• Paradoxical HDL‐C reduction during rosiglitazone and fibrate treatment

  2007cited by this paper
• Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population

  2006cited by this paper
• Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

  2006cited by this paper
• Paradoxically Decreased HDL-Cholesterol Levels Associated with Rosiglitazone Therapy

  2006cited by this paper
• Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.

  2006cited by this paper
• Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

  2004cited by this paper
• Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.

  2004cited by this paper
• Severe Hypo-α-Lipoproteinemia During Treatment With Rosiglitazone

  2004cited by this paper
• Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate

  2002cited by this paper
• The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations.

  2002cited by this paper
• A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate

  2000cited by this paper
• Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

  1998cited by this paper
• Paradoxical High-Density Lipoprotein Reduction Induced by Fibrate Therapy

  1997cited by this paper
• Paradoxical High-Density Lipoprotein Reduction Induced by Fenofibrate and Ciprofibrate

  1996cited by this paper
• High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

  1989cited by this paper
• Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

  1988cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper

• Evaluation of prescription pattern and efficacy of anti-diabetic drugs in Coimbatore, India

  2017cites this paper
• Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.

  2010cites this paper
• Combination of fenofibrate with non-statin drug regimens.

  2010cites this paper
• PARADOxICAl S EVERE DECREASE IN HIgH-DENSITy lIPOPROTEIN CHOl ESTEROl Du E TO ROSIgl ITAz ONE-FENOFIbRATE INTERACTION

  2010cites this paper